STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。假设：（1）罗格列酮与重组人生长激素（rhGH）联合给药将消除rhGH对胰岛素敏感性的不良影响（可能由游离脂肪酸（FFA）周转增加介导），并对减少内脏肥胖具有协同作用;（2）罗格列酮和rhGH对皮下脂肪组织体积的影响将通过其对总能量平衡的影响来确定。主要目的：确定（1）罗格列酮和rhGH对内脏肥胖和胰岛素抵抗的HIV感染受试者胰岛素敏感性的个体和相互作用效应，通过频繁采样的静脉葡萄糖耐量试验进行评估;和（2）罗格列酮和rhGH对HIV-1患者全身MRI和双能X线吸收测定法（DEXA）评估的身体组成的个体和相互作用。内脏肥胖和胰岛素抵抗的受感染者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: that (1) co-administration of rosiglitazone with recombinant human growth hormone (rhGH) will abrogate the adverse effect of rhGH on insulin sensitivity that may be mediated by increased free fatty acid (FFA) turnover and will have a synergistic effect on reducing visceral adiposity; and (2) the effects of rosiglitazone and rhGH on subcutaneous adipose tissue volume will be determined by their effects on total energy balance. Primary Objectives: to determine (1) the individual and interacting effects of rosiglitazone and rhGH on insulin sensitivity, as assessed by frequently sampled intravenous glucose tolerance test, in HIV-infected subjects with visceral adiposity and insulin resistance; and (2) the individual and interacting effects of rosiglitazone and rhGH on body composition assessed by whole body MRI and dual energy X-ray absorptiometry (DEXA) in HIV-infected subjects with visceral adiposity and insulin resistance.